- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.2008 | Central Library of Charles University
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.2008 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Safety and tolerability results of a phase 2b extension study of the novel oral fumarate BG00012 for the treatment of relapsing-remitting multiple sclerosisPublication without faculty affiliation
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study2008 | Second Faculty of Medicine
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study2008 | First Faculty of Medicine
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.2008 | Faculty of Medicine in Pilsen
- Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM2013 | First Faculty of Medicine
- Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study2015 | First Faculty of Medicine